xv 459 has been researched along with elarofiban in 1 studies
| Studies (xv 459) | Trials (xv 459) | Recent Studies (post-2010) (xv 459) | Studies (elarofiban) | Trials (elarofiban) | Recent Studies (post-2010) (elarofiban) |
|---|---|---|---|---|---|
| 15 | 2 | 0 | 5 | 0 | 0 |
| Protein | Taxonomy | xv 459 (IC50) | elarofiban (IC50) |
|---|---|---|---|
| Integrin beta-3 | Homo sapiens (human) | 0.0002 | |
| Integrin alpha-IIb | Homo sapiens (human) | 0.0002 | |
| Polyunsaturated fatty acid 5-lipoxygenase | Homo sapiens (human) | 0.0001 | |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4A | Homo sapiens (human) | 0.0001 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gretler, DD; Scarborough, RM | 1 |
1 review(s) available for xv 459 and elarofiban
| Article | Year |
|---|---|
Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents.
Topics: Administration, Oral; Animals; Antibodies, Monoclonal; Clinical Trials as Topic; Drug Design; Fibrinolytic Agents; Humans; Injections; Integrins; Molecular Mimicry; Peptides; Platelet Glycoprotein GPIIb-IIIa Complex; Snake Venoms | 2000 |